New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePalmitoyl Tetrapeptide-7 vs Cardiogen

Palmitoyl Tetrapeptide-7 vs Cardiogen

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Anti-Aging & Longevity
Cardiogen
Summary
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Half-Life
Topical penetration-dependent; effects last hours to days
Short (minutes); gene-regulatory effects persist longer
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
2-5 ppm concentration in formulation
10 mg per day
Frequency
Twice daily
Daily for 10–30 days
Key Benefits
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
Side Effects
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
Stacks With